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Epigenetic gene silencing is an important mechanism in
the initiation and progression of cancer. Abnormal DNA
CpG island hypermethylation and histone modiﬁcations are
involved in aberrant silencing of tumour-suppressor genes.
LSD1 (lysine-speciﬁc demethylase 1) was the ﬁrst enzyme
identiﬁed to speciﬁcally demethylate H3K4 (Lys
4 of histone
H3). Methylated H3K4 is an important mark associated with
transcriptional activation. The ﬂavin adenine dinucleotide-
binding amine oxidase domain of LSD1 is homologous with
two polyamine oxidases, SMO (spermine oxidase) and APAO
(N
1-acetylpolyamine oxidase). We have demonstrated previously
that long-chain polyamine analogues, the oligoamines, are
inhibitors of LSD1. In the present paper we report the synergistic
effects of speciﬁc oligoamines in combination with DFMO (2-
diﬂuoromethylornithine),aninhibitorofornithinedecarboxylase,
in human colorectal cancer cells. DFMO treatment depletes
natural polyamines and increases the uptake of exogenous
polyamines. The combination of oligoamines and DFMO results
in a synergistic re-expression of aberrantly silenced tumour-
suppressor genes, including SFRP2 (secreted frizzled-related
protein 2), which encodes a Wnt signalling pathway antagonist
and plays an anti-tumorigenic role in colorectal cancer. The
treatment-induced re-expression of SFRP2 is associated with
increased H3K4me2 (di-methyl H3K4) in the gene promoter.
The combination of LSD1-inhibiting oligoamines and DFMO
represents a novel approach to epigenetic therapy of cancer.
Key words: epigenetic, histone, lysine-speciﬁc demethylase 1
(LSD1), ornithine decarboxylase, polyamine.
INTRODUCTION
Aberrant epigenetic silencing of gene expression is an important
mechanism in the genesis and progression of cancer [1].
Epigenetic changes in chromatin, including DNA methylation
of gene promoter region CpG islands, collaborate with
histone modiﬁcations, including methylation, acetylation and
phosphorylation, to regulate gene expression. The acetylation of
histones is generally associated with active gene transcription [2].
However, the role of histone methylation is context dependent.
Typically, methylation at H3K4 (Lys
4 of histone 3), H3K36 and
H3K79 is involved in active transcription, whereas methylation at
H3K9 (Lys
9 of histone H3) and H3K27 (Lys
27 of histone H3) is
associated with transcriptional silencing [3]. Histone methylation
wasconsideredanirreversibleprocessuntilthediscoveryofLSD1
(lysine-speciﬁc demethylase 1) [4]. LSD1 (also named AOF2,
BHC110, KDM1 and KIAA0601) interacts with the co-repressor
complex CoREST (repressor element 1-silencing transcription
factor co-repressor) and HDAC1/2 (histone deacetylase 1/2) and
is able to demethylate H3K4me1 (mono-methyl H3K4) and
H3K4me2 (di-methyl H3K4) on nucleosomes [5]. LSD1 is a
FAD-dependent amine oxidase and its catalytic domain has over
60%aminoacidsequencesimilaritywithtwoimportantenzymes
in polyamine catabolism, SMO (spermine oxidase) and APAO
(N
1-acetylpolyamine oxidase) [4,6]. This homology suggests the
strategy of pursuing polyamine analogues as LSD1 inhibitors to
regulatechromatinremodelling.Ourlaboratoryhasdemonstrated
previously that speciﬁc polyamine analogues function as potent
inhibitorsofLSD1[6–9].Inspeciﬁcinstances,inhibitionofLSD1
by polyamine analogues results in the re-expression of genes
that are aberrantly silenced in cancer. These results have been
conﬁrmed both in vitro and in vivo [7,10]. In vivo treatment
of established human tumours in nude mice demonstrated that
long-chain polyamine analogues (oligoamines) effectively inhibit
LSD1 in situ, resulting in a dramatic decrease in tumour size.
In vitro results with the oligoamines demonstrated that treatment
of cancer cells results in increased methylated H3K4, the
target of LSD1, and increased expression of various previously
silenced genes. Each of these results is consistent with the
hypothesis that inhibition of LSD1 by the oligoamines is
responsible for the re-expression of the silenced genes.
The natural polyamines are cationic alkylamines that are
positively charged at physiological pH (Figure 1) [11–14]. They
are closely associated with chromatin and are thought to have
a role in the regulation of multiple cellular functions, including
geneexpression.DFMO(2-diﬂuoromethylornithine),aninhibitor
of the ﬁrst rate-limiting enzyme in polyamine biosynthesis,
ODC (ornithine decarboxylase) [15], can be used to reduce
intracellular polyamine concentrations, both in vitro and in vivo
[16].Wehypothesizedthatthereductionofthenaturalpolyamines
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Figure 1 Structures of the natural polyamines and oligoamines
in cancer cells by pre-treatment with DFMO would enhance
the epigenetic effects of oligoamine treatment through two
mechanisms: (i) the reduction of the natural polyamines would
allow the analogues to have greater access to their targets; and
(ii) the reduction of natural polyamines would result in increased
uptake of the oligoamines, thus rapidly increasing the effective
intracellular analogue concentration. Therefore we examined the
effects of treating human tumour cells with the combination of
DFMO and speciﬁc oligoamine analogues.
The results of the present study indicate that this combination
of an ODC inhibitor with a polyamine analogue-based LSD1
inhibitor can produce synergistic effects with regard to increased
expression of aberrantly silenced tumour-suppressor genes and
enrichment of H3K4me2 active marks at the gene promoter.
This combination therefore represents a completely novel anti-
proliferative therapeutic approach to the treatment of cancer.
EXPERIMENTAL
Compounds, culture conditions and treatment
DFMO was from the DFMO repository at the Medical University
of South Carolina, Charleston, SC, U.S.A. (Professor Patrick
Woster).TranylcyprominewaspurchasedfromSigma.Polyamine
analogues (Figure 1) were provided by Progen Pharmaceuticals.
Stock solutions of each compound were diluted with medium
to the desired concentrations for speciﬁc experiments. HCT116
human colorectal carcinoma cells were maintained in McCoy’s
5A medium and HT-29 colorectal adenocarcinoma cells were
maintained in DMEM (Dulbecco’s modiﬁed Eagle’s medium),
each supplemented with 9% FBS (fetal bovine serum; Atlanta
Biologicals) and 1% penicillin/streptomycin (Mediatech), and
grown at 37◦Ci na5% CO2 atmosphere. Where indicated, the
cells were ﬁrst treated for 24 h with 5 mM DFMO, followed by
another 24 h treatment of replenished 5 mM DFMO, either alone
orsimultaneouslywithapolyamineanalogueortranylcypromine,
at the indicated concentrations.
Determination of cell viability and mechanism of cell death
HCT116cellswereseededat6000cells/wellin100 μlofmedium
in 96-well plates. Cells were ﬁrst treated for 24 h with 5 mM
DFMO, followed by another 24 h treatment with replenished
5 mM DFMO and PG-11144, alone or simultaneously, at the in-
dicated concentrations. MTS [3-(4,5-dimethylthiazol-2-yl)-5-(3-
carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium] re-
agent (20 μl; Promega) was added to the medium. The cells
were incubated for another 2 h and absorbance was measured at
490 nm on a microplate reader (Molecular Devices) to determine
the cell viability. To determine whether cell death induced by
the combination treatment occurred through apoptosis, PARP
[poly(ADP-ribose) polymerase] cleavage analysis was performed
as reported previously [7].
Western blotting
Whole-cell lysates were extracted using RIPA buffer [10 mM
sodium phosphate (pH 7.5), 150 mM NaCl, 1% Nonidet
P40, 0.5% sodium deoxycholate and 0.1% SDS]. Primary
antibodiesagainstPARPandactinwerefromInvitrogenandSanta
Cruz Biotechnology respectively. Dye-conjugated secondary
antibodies were used for quantiﬁcation of the Western blot results
using the Odyssey infrared detection system and software (LI-
COR Biosciences).
HPLC
HCT116 cell extract was prepared using SSAT (sperm-
idine/spermine acetyltransferase) breaking buffer [5 mM Hepes
(pH 7.2) and 1 mM dithiothreitol)]. Concentrations of individual
polyamine pools and PG-11144 were quantiﬁed using dansyl
chloride labelling followed by HPLC, as described previously
[17].
RNA isolation and qPCR (quantitative PCR)
RNA was extracted using TRIzol® reagent (Invitrogen).
First-strand cDNA of HCT116 cells was synthesized using
M-MLV (Moloney murine leukaemia virus) reverse transcriptase
with an oligo(dT)12–18 primer. For HT-29 cells, Superscript III
reverse transcriptase with oligo(dT)20 primers (Invitrogen) was
used to synthesize ﬁrst-strand cDNA. qPCR was performed
in a MyiQ single-colour real-time PCR detection system
(Bio-Rad Laboratories) with GAPDH (glyceraldehyde-3-
phosphate dehydrogenase) as an internal control. The CDKN2A
(cyclin-dependent kinase inhibitor 2A) primers used were:
sense, 5
 -CAATCGGGGATGTCTGAGGGAC-3
  and antisense,
5
 -CGGAGGCCGATCCAGGTCATG-3
  (annealing at 67.3◦C).
The GATA4 (GATA-binding protein 4) primers used were: sense,
5
 -GGCCGCCCGACACCCCAATCT-3
  and antisense, 5
 -AT-
AGTGACCCGTCCCATCTCG-3
  (annealing at 65◦Cf o r
HCT116 cells and 58◦C for HT-29 cells). The GATA5 primers
used were: sense, 5
 -CCTGCGGCCTCTACCACAA-3
  and
antisense, 5
 -GGCGCGGCGGGACGAGGAC-3
  (annealing
at 64.3◦C for HCT116 cells and 65◦C for HT-29 cells). The
SFRP1 (secreted frizzled-related protein 1) primers used were:
sense, 5
 -GGCCCATCTACCCGTGTCG-3
  and antisense,
5
 -GATGGCCTCAGATTTCAACTCGT-3
  (annealing at 60◦C).
The SFRP2 primers used were: sense, 5
 -AAGCCTGCAAA-
AATAAAAATGATG-3
  and antisense, 5
 -TGTAAATGGTCT-
TGCTCTTGGTCT-3
  (annealing at 63◦C for HCT116 cells
and 59.3◦C for HT-29 cells). For HCT116 cells, the SFRP4
primers used were: sense, 5
 -TCTTCTTGCCAGTGTCCAC-3
 
and antisense, 5
 -GGCTGTTTTCTTCTTGTCCTG-3
 
(annealing at 61.2◦C). For HT-29 cells, the SFRP4 primers used
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Figure 2 Viability of HCT116 cells following treatment with DFMO in combination with PG-11144
Cellsweretreatedfor24hwith5mMDFMOfollowedbya24htreatmentwithreplenished5mMDFMOandPG-11144attheindicatedconcentrations(μM),aloneorsimultaneously,andcellviability
was measured by an MTS assay. Shown is the percentage of viable cells in treatment groups relative to untreated control cells. Results are means+ −S.D. of treatments performed in quadruplicate
from a representative experiment performed three times.
were: sense, 5
 -TCTATGACCGTGGCGTGTGC-3
  and anti-
sense, 5
 -ACCGATCGGGGCTTAGGCGTTTAC-3
  (annealing
at 65◦C). The SFRP5 primers used were: sense, 5
 -GCGAGG-
AGTACGACTACTATG-3
  and antisense, 5
 -AAAGAGC-
GAGCACAGGAAG-3
  (annealing at 61.2◦C for HCT116 cells
and 65◦C for HT-29 cells). Ampliﬁcation conditions consisted of
a 15 min denaturation step followed by 40 cycles of denaturation
at 95◦C for 30 s, annealing at the designated temperature for 30 s
and extension at 72◦C for 30 s.
ChIP (chromatin immunoprecipitation)
ChIP analysis was performed using Protein A and Protein
G Dynabeads® (Invitrogen). Cells were exposed to 1%
formaldehyde to cross-link proteins, and 2×10
6 cells were used
for each ChIP assay. The antibody against pan H3 was from
Abcam and antibodies against H3K4me1, H3K4me2, H3K9me2
(di-methyl H3K9), acetyl-H3K9 and LSD1 were from Millipore.
Quantitative ChIP was performed using qPCR on the MyiQ
single-colourreal-timePCRdetectionsystem.PCRprimersspan-
ning the proximal SFRP2 promoter region from approximately
−800 bpto −600 bprelativetotheTSS(transcriptionalstartsite)
were used for ampliﬁcation. The sequences of the primers were:
sense, 5
 -CCTGTGTGACTGGTGAGACTC-3
  and antisense,
5
 CGGCGAACTTCGTTTTCCCTC-3
  (annealing at 63.3◦C).
Sheared genomic DNA was used as a positive control (input) and
for normalization of DNA immunoprecipitated by LSD1. DNA
immunoprecipitated by the anti-(pan H3) antibody was used for
normalization for the histone H3 modiﬁcations.
Bisulﬁte sequencing
Genomic DNA from HCT116 cells was bisulﬁte modiﬁed
using the EZ DNA Methylation kit (Zymo Research) and
bisulﬁte sequencing of the SFRP2 gene promoter was performed
using the following primers: sense, 5
 -GGTAATTTAGTA-
GAAATTTCGGATTG-3
  and antisense, 5
 -ACTAATCACT-
ACTTTCTAAATCTAATT-3
 . A total of 15 clones were analysed
for each treatment condition.
RESULTS
The combination of DFMO and PG-11144 leads to decreased
cell viability
To determine the effects of the combination of DFMO and
an oligoamine on cell proliferation, HCT116 human colorectal
carcinoma cells were ﬁrst treated for 24 h with 5 mM DFMO,
followed by another 24 h treatment with DFMO and PG-11144 at
theindicatedconcentrations.TreatmentwithPG-11144alonewas
alsoevaluated.AnMTSassaywasusedtodeterminecellviability
(Figure 2). The results demonstrated that PG-11144 alone leads
to a moderate reduction in viable cells at high concentrations
(79% of cells are viable at 5 μM and 64% at 10 μM, relative to
control), whereas, as expected, DFMO alone had no signiﬁcant
effects on cell viability. The anti-proliferative effect of PG-11144
was augmented when DFMO was added to the combination, with
2.5 μMa n d5μM PG-11144 reducing viable cells to 50% and
32% respectively. PG-11144 (10 μM) plus DFMO produced the
most prominent cytotoxicity, decreasing viable cells to 11% of
that of untreated cells.
To determine whether the increased cell death following the
combined treatment of PG-11144 and DFMO was a result of
increased apoptosis, we examined the changes in PARP cleavage
as an indicator of apoptosis as we have published previously
[7]. Western blot analysis indicates that PG-11144 alone at 5
and 10 μM induces robust PARP cleavage. When combined with
DFMO,PG-11144atalowerconcentration(2.5 μM)iscapableof
inducing signiﬁcant PARP cleavage (Supplementary Figure S1 at
http://www.BiochemJ.org/bj/442/bj4420693add.htm). ThePARP
cleavage data are entirely consistent with the observed synergy
of the combination and indicate that apoptosis is the underlying
mechanism of the observed cell death.
Effects of treatment with the combination of DFMO and the
oligoamine PG-11144 on polyamine pools
NaturalpolyaminesareknowntoassociatewithDNAandresultin
conformationalchangesandaggregationofDNA[18,19].Speciﬁc
polyamine analogues utilize the polyamine transporter for entry
into the cell, where they exert effects on natural polyamine
concentrations via regulation of polyamine biosynthesis and
catabolism,potentiallyresultinginchangesinchromatinstructure
[20]. We hypothesized that the addition of DFMO, an inhibitor
of a rate-limiting enzyme in polyamine synthesis, ODC [15],
wouldincreaseuptakeofPG-11144anddecreaselevelsofnatural
polyamines,allowinggreateraccessoftheanaloguetochromatin.
ThereforetheeffectsofthecombinationofDFMOandPG-11144
treatment on polyamine pools in HCT116 cells were determined
by HPLC (Table 1). As expected, the cellular levels of putrescine
and spermidine were depleted by DFMO treatment. Treatment
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Table 1 Effects of combining treatment with DFMO and the oligoamine PG-11144 on polyamine pools in HCT116 cells
HCT116 cells were treated for 24h with or without 5mM DFMO, followed by another 24h treatment with refreshed medium containing 5mM DFMO and the indicated doses of PG-11144, alone
or in combination. Intracellular concentrations of putrescine, spermidine, spermine and PG-11144 were measured by HPLC. Each of the values represents the mean of two determinations of one
treatment from a representative experiment performed three times.
Polyamine concentration (nmol/mg of protein)
Treatment Putrescine Spermidin Spermine PG-11144
Untreated 2.5 9.5 15.2 0.0
DFMO 5 nM 0.0 0.2 6.7 0.0
PG-11144 0.5μM 2.7 5.0 7.6 0.0
PG-11144 1μM 2.5 4.3 6.4 0.5
PG-11144 2.5μM 2.2 3.2 4.3 1.0
PG-11144 5μM 0.0 3.2 4.6 1.7
PG-11144 10μM 0.0 3.2 6.2 2.3
DFMO 5 mM + PG-11144 0.5μM 0.0 1.1 6.7 2.3
DFMO 5 mM + PG-11144 1μM 0.0 1.2 4.1 1.9
DFMO 5 mM + PG-11144 2.5μM 0.0 1.2 4.6 2.8
DFMO 5 mM + PG-11144 5μM 0.0 1.1 5.7 6.0
DFMO 5 mM + PG-11144 10 μM 0.0 0.9 7.8 11.5
with PG-11144 alone led to a decrease in all three polyamines
in a dose-dependent manner. This decrease is probably due to
the down-regulation of ODC caused by PG-11144 as we have
publishedpreviously[21,22].ThecombinationofPG-11144with
DFMO did not lead to a greater decrease in natural polyamine
poolsthanthatachievedwithDFMOalone.However,intracellular
levelsofPG-11144weresigniﬁcantlyincreasedwhenDFMOwas
used in combination with PG-11144, as compared with treatment
with PG-11144 alone. In the presence of DFMO, the addition
of PG-11144 at a dose as low as 0.5 μM resulted in a level of
intracellular PG-11144 comparable with that seen following
treatment with 10 μM PG-11144 alone. Furthermore, treatment
with 5 or 10 μM PG-11144 in combination with DFMO led to
a signiﬁcant increase in the intracellular concentration of PG-
11144. These data validate our hypothesis that DFMO, in com-
binationwithanoligoamine,notonlyreducesnaturalpolyamines,
but also enhances intracellular levels of the analogue, which may
result in greater effectiveness of oligoamines on their targets.
The combination of DFMO plus oligoamines results in synergistic
re-expression of multiple aberrantly silenced genes
To determine whether the combination of the oligoamines and
DFMO results in synergistic re-expression of previously silenced
genes, we examined the expression level of the Wnt-signalling
antagonist SFRP2. SFRP2 is a gene frequently silenced in colon
cancers, as represented by the HCT116 colorectal cancer cell line
[23]. HCT116 cells were pre-treated for 24 h with 5 mM DFMO,
followed by a 24 h co-treatment with replenished
5 mM DFMO, either alone or with a polyamine analogue
or tranylcypromine at 5 μM. The results indicate that each of
the oligoamines tested in combination with DFMO induced
synergistic re-expression of the previously silenced SFRP2
gene. We also observed that PG-11144 and PG-11150 were
effective as single agents in increasing SFRP2 expression level,
as reported previously [7] (Figure 3A). The synergistic gene
re-activation effects were not limited to HCT116 cells. Another
human colorectal cancer cell line, HT-29, was also examined,
and the combination of DFMO and oligoamine treatment
showed increases not only in re-expression of SFRP2,b u ta l s o
in the expression of the aberrantly silenced CDKN2A (p16)
gene (Figure 3B). In addition, genes of the GATA family of
transcription factors, GATA4 and GATA5, and of three other
members of the SFRP family, SFRP1, SFRP4 and SFRP5,
were examined in HCT116 cells (Supplementary Table S1a
at http://www.BiochemJ.org/bj/442/bj4420693add.htm); these
genes were also examined in HT-29 cells except GATA5 and
SFRP1 (Supplementary Table S1b). In both of the colorectal
cancer cell lines, the combination of DFMO with the various
oligoamines resulted in a cell type-speciﬁc response with regard
to which speciﬁc genes were re-expressed, with the SFRP2 gene
demonstrating the greatest re-expression. Tranylcypromine, a
non-selective MAO (monoamine oxidase) inhibitor commonly
used as antidepressant medication, has been demonstrated
to inhibit LSD1-mediated demethylation of H3K4 [24–26].
However, treatment with tranylcypromine, either alone or in
combination with DFMO, did not induce re-expression of the
aberrantly silenced SFRP2 gene in HCT116 or HT-29 cells,
in clear contrast with the results seen with the oligoamines. A
modest increase in expression of genes other than SFRP2 was
observed in HCT116 cells (SFRP1) and in HT-29 cells (CDKN2A
and SFRP5) when these cells were treated with tranylcypromine
alone or in combination with DFMO. It should be noted that
tranylcypromine lacks the cationic nature of the oligoamines,
thus, unlike the oligoamines, it is not targeted to chromatin.
These data suggest that inhibition of LSD1 by tranylcypromine
and the oligoamines differs in functional outcome.
Synergistic re-expression of SFRP2 in response to combined
DFMO and PG-11144 is dose-dependent on PG-11144
To further evaluate that DFMO pre-treatment increased the
effectiveness of PG-11144, we examined the dose dependency
of SFRP2 gene re-expression with increasing concentrations of
PG-11144 in combination with 5 mM DFMO. A dose as low
as 0.5 μM PG-11144 demonstrated synergy with DFMO. The
synergy reached its maximum when 5 μM PG-11144 was used
in combination with DFMO (Figure 4). Higher concentrations
actually resulted in less SFRP2 expression, probably as a result
of increased cytotoxicity.
The combination of DFMO with PG-11144 alters histone
modiﬁcations in the promoter region of the SFRP2 gene
To investigate whether the synergistic re-expression of aberrantly
silenced genes was linked to LSD1 inhibition and changes in
chromatin that favour transcription, the levels of various histone
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Figure 3 Synergy of oligoamines and DFMO in the re-expression of aberrantly silenced genes
HCT116 cells (A)o rH T - 2 9c e l l s( B) were ﬁrst treated for 24h with 5 mM DFMO, followed by another 24h treatment with replenished 5 mM DFMO, either alone or simultaneously with a polyamine
analogue or tranylcypromine at 5 μM. (A) Transcript expression of SFRP2 in HCT116 cells was analysed by qPCR. (B) For HT-29 cells, qPCR was performed to analyse the transcript expression
levels of SFRP2 and CDKN2A. For both cell lines, GAPDH was used as an internal control. Results are the means+ −S.D. of three independent treatments with the real-time PCR performed in
triplicate. The transcript level for control untreated samples was set to a value of 1.
Figure 4 Dose response to PG-11144, in co-treatment with DFMO, for the synergistic re-expression of SFRP2
HCT116cellsweretreatedfor24hwith5mMDFMO,followedbyanother24htreatmentwithreplenished5mMDFMOandPG-11144intheindicateddoses(μM),aloneorsimultaneously.Results
are means+ −S.D. of real-time PCR analysis of three independent treatments with the PCR performed in triplicate. GAPDH was used as an internal control. The transcript level for control samples
was set to a value of 1.
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Figure5 EffectsofDFMOincombination withPG-11144onvarioushistone
marks and LSD1 at the promoter of SFRP2
HCT116 cells were ﬁrst treated for 24h with 5mM DFMO followed by another 24h treatment
with replenished 5mM DFMO and PG-11144 in the indicated doses, alone or simultaneously.
Quantitative ChIP analysis was performed with H3 as control for immunoprecipitation of
protein–DNA complexes. Results are means+ −S.D. of three independent real-time ChIP
experiments with PCR performed in triplicate. The relative enrichment of histone marks or
LSD1 levels for untreated control samples were set to a value of 1.
modiﬁcations in the promoter of SFRP2 were examined in
HCT116 cells. ChIP analysis of the promoter region of SFRP2
clearly demonstrated a signiﬁcant increase in H3K4me2, the
target of LSD1 and a transcriptional activating mark, when 5 μM
PG-11144 was combined with DFMO (Figure 5). However, no
induction was detected for the relative enrichment of H3K4me1,
which is another substrate of LSD1. Interestingly, the level of
the repressive mark H3K9me2 in the SFRP2 promoter region
exhibited a modest increase when treated with DFMO, either
alone or in combination with PG-11144. In contrast, a slight
decrease in the H3K9me2 mark was observed when cells were
treated with 2.5 μM PG-11144 alone. The level of the activating
mark, acetyl-H3K9, demonstrated a marginal decrease, probably
because acetylation and methylation at the same histone site are
mutually exclusive [27]. Occupancy of LSD1 at the promoter
of SFRP2 was reduced by PG-11144 treatment alone. The
LSD1 level in the adjacent SFRP2 promoter region (spanning
approximately −1000 bp to −800 bp relative to the TSS) was
also examined, and a consistent reduction of LSD1 was observed
after exposure to PG-11144, alone or in combination with DFMO
(results not shown).
DNA methylation status of the SFRP2 promoter is not affected by
DFMO in combination with PG-11144
DFMO inhibits ODC and consequently depletes putrescine.
Reducing the level of putrescine leads to accumulation
of dcSAM (decarboxylated S-adenosylmethionine), which is
the aminopropyl group donor in spermidine and spermine
synthesis [28]. dcSAM acts as a competitive inhibitor of
S-adenosylmethionine, the methyl group donor for methylation
reactions, and could subsequently result in interference
with DNMT (DNA methyltransferase) activity and changes in
DNA methylation [29]. Bisulﬁte sequencing was performed to
determine the CpG island methylation status in the SFRP2
promoter with and without treatment (Figure 6). No signiﬁcant
changes in SFRP2 promoter methylation were observed with
either DFMO or PG-11144, alone or in combination (frequencies
of unmethylated CpG sites for control, 5 mM DFMO alone,
5 μM PG-11144 alone or DFMO in combination with PG-11144
were 4.37%,5 . 2 9 %,4 . 3 7 % and 4.60% respectively). These
results indicate that the increase in transcription induced by the
combination of DFMO and PG-11144 is not dependent upon
changes in promoter DNA CpG island methylation.
DISCUSSION
Epigenetic silencing of gene expression plays a key role in
the aetiology and progression of cancer [1,30,31]. Strategies to
reverse aberrant gene silencing have been demonstrated to be
efﬁcacious in speciﬁc cancers, and clinical trials are ongoing to
evaluate drugs targeting epigenetic regulation of gene expression
[32,33]. Targeting epigenetic changes is an attractive strategy,
as these changes, unlike gene loss or mutation, are reversible.
To date, most of the drugs studied that alter epigenetic gene
regulation have targeted either the DNMTs or the HDACs.
However, other signiﬁcant targets exist. With the discovery of
thetranscriptionallyrepressivelysine-speciﬁcdemethylaseLSD1
[4] it was hypothesized that inhibition of this enzyme could
lead to the re-expression of some aberrantly silenced genes. As
an FAD-dependent amine oxidase, LSD1 is structurally similar
to, and functions in a mechanistically similar manner as, the
polyamine oxidases [4,7,34,35]. We therefore postulated, and
have since demonstrated, that speciﬁc polyamine analogues can
effectively inhibit LSD1 activity, increase promoter-bound levels
of H3K4me2 and lead to re-expression of previously silenced
genes [7,10].
The studies presented in the present paper demonstrate that
pre-treatmentofhumancoloncancercellswiththeODCinhibitor
DFMO, followed by co-treatment with DFMO and the polyamine
analogue LSD1 inhibitor, results in intracellular polyamine de-
pletion, increased accumulation of analogue, synergistic re-
expression of an aberrantly silenced geneand increased cell death
throughapoptoticmechanisms.However,thedeterminationofthe
precise gene expression changes leading to increased apoptosis
will require additional study.
The natural polyamines are known to play a role in chromatin
structure and their cationic nature at physiological pH makes
them important counter ions to the phosphate backbone of DNA
[11]. There are no data to indicate that the natural polyamines are
inhibitors of, or substrates for, LSD1 [4]; however, it is possible
that the reduction of intracellular polyamine concentrations alters
chromatin conformation and/or makes the target, LSD1, more
accessible to the oligoamine inhibitors.
The ChIP analysis of the present study demonstrates that PG-
11144 alone down-regulates LSD1 occupancy in speciﬁc regions
of the SFRP2 promoter (spanning approximately −800 bp to
−600 bp relative to the TSS) (Figure 4). We also observed that
in the adjacent region, approximately −1000 bp to −800 bp
relative to the TSS, the LSD1 level was reduced by PG-11144,
both alone and in combination with DFMO (results not shown).
PG-11144 is a long-chain polyamine analogue that possesses
a multivalent (+10) cationic structure, and thus has higher
afﬁnity for chromatin than natural polyamines [36]. PG-11144
could bind to, and alter, chromatin structure, thus decreasing the
ability of LSD1 to target the nucleosome at speciﬁc chromatin
sites, thereby leading to a decrease of LSD1 occupancy at the
SFRP2 promoter. In the presence of DFMO, this effect could be
augmented in certain promoter regions due to the lower level of
natural polyamines and higher accessibility of the oligoamine to
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Figure 6 Effects of oligoamine and DFMO treatment on promoter CpG island methylation of SFRP2
HCT116 cells were ﬁrst treated for 24h with 5mM DFMO followed by another 24h treatment with replenished 5mM DFMO and 5 μM PG-11144, alone or simultaneously. Genomic DNA
from HCT116 cells was bisulﬁte modiﬁed and sequencing of the promoter of the SFRP2 gene was performed. The methylation status of 29 CpG sites in the promoter region of SFRP2 was assessed.
Each circle represents one CpG site that is methylated (closed circle) or unmethylated (open circle) and each horizontal line shows the methylation status of CpG sites for a single cloned allele. A
total of 15 clones were analysed for each treatment condition.
chromatin. Further work will be necessary to speciﬁcally test this
hypothesis at this and other gene promoters.
Itisnotablethattheresultsofthepresentstudydemonstratethat
not only the transcriptional activating mark H3K4me2, but also
therepressivemarkH3K9me2,wereincreasedbythecombination
treatment. LSD1 was reported to demethylate H3K9me2 when
interacting with androgenreceptoror oestrogenreceptor [37–41];
however,morestudieswillbenecessarytodeterminewhetherthis
increased H3K9me2 is correlated with changes in LSD1 activity
or is potentially due to broader effects on repressor complex
formation. The simultaneous increase in both transcriptional
activating and repressive marks indicates the complexity of the
gene regulation mechanisms underlying the response to co-
treatment with DFMO and the oligoamines.
DFMO-induced reduction of the levels of putrescine and
spermidine results in a subsequent accumulation of dcSAM,
which could contribute to DNMT inhibition [29]. In addition,
OAZ (ODC antizyme-1), a molecule that promotes ODC
degradation and thereby induces polyamine depletion, was
reported to induce hypomethylation of genomic DNA and
decreaseH3K9me2inahumanoralcancercellline[42].However,
the results of the present study demonstrate that treatment with
DFMO, alone or in combination with PG-11144, had no effects
on the methylation level of CpG islands in the SFRP2 promoter.
Furthermore, the addition of the DNMT inhibitor, 5-azacytidine,
to the DFMO and PG-11144 combination treatment regimen
in HCT116 cells showed no advantage with respect to SFRP2
re-expression (results not shown). These results imply that the
chromatin-modifying effects induced by DFMO in combination
with the oligoamines might be sufﬁcient to result in the high level
ofSFRP2re-expressiondetected,independentofchangesinDNA
CpG island methylation.
The combination of DFMO and the oligoamines may have
particular signiﬁcance in colon cancer. Chemoprevention studies
by Gerner and colleagues [43] demonstrated that DFMO is a
well-tolerated and promising drug for the prevention of sporadic
colorectal adenomas. These studies, combined with our own
ﬁnding that PG-11144 alone is effective in shrinking established
HCT116 human colon tumours in nude mice [7], suggest the
potential for added beneﬁt in the colon tumour setting. However,
further in vivo studies will be necessary to determine the efﬁcacy
and any potential toxic side effects of this combination in both
therapeutic and chemopreventive settings.
Increased intracellular polyamines have been implicated in
alterations in histone acetyltransferases and HDACs, potentially
resulting in epigenetic changes that lead to the initiation and
progression of tumours in a transgenic mouse model where
ODC, the target of DFMO, is overexpressed [44–46]. Another
previous report indicates that polyamine depletion by DFMO
can induce differentiation in cardiac myocytes through epigenetic
mechanisms [47]. Taken together, these ﬁndings are relevant in
thattheysuggestthatinhibitionofpolyaminesynthesisbyDFMO
may reduce or block some epigenetic changes necessary for
cancer. Thus the effective combination of the oligoamine LSD1
inhibitors with DFMO may be a result of multiple beneﬁcial
mechanisms.
In summary, we have demonstrated that the LSD1-inhibiting
oligoamines, in combination with the ODC inhibitor DFMO,
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results in increased expression of important tumour-suppressor
genes,includingSFRP2andCDKN2A,whichareoftenaberrantly
silenced in colon cancer, as well as other solid tumour
and haematological malignancies. Importantly, this combination
results in a synergistic response in treated cells that alters
local chromatin and results in the re-expression of these
important tumour-suppressor genes. This combination represents
a promising and entirely unique strategy for the targeting of
epigenetically silenced genes in the treatment of cancer.
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Figure S1 Induction of PARP cleavage by PG-11144 alone or
simultaneously with DFMO
HCT116cellswereﬁrsttreatedfor24hwith5 mMDFMOfollowedbyanother24 htreatmentof
replenished 5 mM DFMO and PG-11144 in the indicated doses (μM) alone or simultaneously.
Total protein was extracted and analysed by Western blotting using antibodies that recognize
full-length and cleaved PARP. The positions of the 116 kDa full length and the 85 kDa cleaved
PARP are indicated on the right. Actin was used as a loading control. Molecular mass is given
in kDa on the right-hand side.
1 Robert Casero and Laurence Marton have applied for a patent to cover the combination of agents described in the present paper.
2 To whom correspondence should be addressed (email rcasero@jhmi.edu).
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Table S1 Effects of treatment with the combination of DFMO and oligoamine on transcript expression levels of aberrantly silenced genes
HCT116 (a) and HT-29 (b) cells were ﬁrst treated for 24h with 5 mM DFMO, followed by another 24h treatment with replenished 5mM DFMO, either alone or simultaneously with a polyamine
analogue or tranylcypromine at 5 μM. (a) Transcript expression of GATA4, GATA5, SFRP1, SFRP2, SFRP4 and SFRP5 in HCT116 cells was analysed by qPCR. (b) For HT-29 cells, qPCR was
performed to analyse the transcript expression levels of CDKN2A, GATA4, SFRP2, SFRP4 and SFRP5. GAPDH was used as internal control for all of the qPCR analyses. The results are the means
of three independent treatments with the real-time PCR performed in triplicate. The transcript level for untreated control samples was set to a value of 1.
(a)
Treatment GATA4 GATA5 SFRP1 SFRP2 SFRP4 SFRP5
DFMO 5 mM 09+ −0.1 1.2+ −0.4 1.2+ −0.1 1.0+ −0.1 0.9+ −0.1 0.6+ −0.1
PG-11144 5μM1 . 2 + −0.1 0.9+ −0.3 1.9+ −0.8 4.8+ −0.5 0.7+ −0.1 0.7+ −0.1
PG-11150 5μM0 . 6 + −0.3 0.3+ −0.1 2.4+ −0.7 25.2+ −2.8 2.5+ −1.0 1.3+ −0.9
PG-11157 5μM2 . 1 + −0.2 0.9+ −0.2 1.0+ −0.5 1.6+ −0.4 1.2+ −0.1 0.7+ −0.1
PG-11158 5μM2 . 3 + −1.0 1.8+ −0.5 1.1+ −0.1 0.7+ −0.1 0.6+ −0.1 0.6+ −0.2
PG-11159 5μM1 . 6 + −0.4 1.0+ −0.1 0.6+ −0.4 3.0+ −0.9 0.3+ −0.0 0.2+ −0.0
PG-11179 5μM1 . 2 + −0.1 1.5+ −0.3 2.7+ −0.6 2.2+ −0.3 1.6+ −0.1 0.5+ −0.2
Tranylcypromine 5μM0 . 3 + −0.1 0.9+ −0.3 4.9+ −1.1 1.3+ −0.4 1.3+ −0.1 0.4+ −0.1
DFMO 5mM + PG-11144 5μM2 . 3 + −0.7 1.6+ −0.3 5.6+ −1.9 120.6+ −37.8 2.1+ −0.3 0.9+ −0.2
DFMO 5mM + PG-11150 5μM4 . 4 + −0.5 2.0+ −0.9 8.3+ −1.8 260.4+ −89.0 7.1+ −0.7 3.6+ −0.4
DFMO 5mM + PG-11157 5μM2 . 8 + −0.4 2.2+ −0.1 1.2+ −0.4 154+ −9.3 2.2+ −0.3 2.4+ −2.0
DFMO 5mM + PG-11158 5μM1 . 5 + −0.2 1.6+ −0.6 1.3+ −0.4 195.4+ −59.5 1.6+ −0.1 1.1+ −0.3
DFMO 5mM + PG-11159 5μM2 . 7 + −1.0 2.3+ −0.7 3.3+ −1.3 263.8+ −56.8 3.7+ −0.7 2.9+ −0.8
DFMO 5mM + PG-11179 5μM2 . 4 + −0.3 1.5+ −0.4 18.1+ −5.7 35.2+ −6.4 4.8+ −1.2 1.4+ −0.1
DFMO 5mM + Tranylcypromine 5μM0 . 9 + −0.2 0.7+ −0.1 2.3+ −0.5 0.7+ −0.3 0.8+ −0.1 0.2+ −0.1
(b)
Treatment CDKN2A GATA4 SFRP2 SFRP4 SFRP5
DFMO 5 mM 0.8+ −0.2 1.3+ −0.2 0.8+ −0.2 1.1+ −0.3 5.3+ −0.2
PG-11144 5μM1 . 2 + −0.1 2.6+ −0.4 1.8+ −0.2 1.4+ −0.4 22.3+ −5.2
PG-11150 5μM1 . 0 + −0.6 1.3+ −0.3 0.9+ −0.0 0.5+ −0.1 3.1+ −3.1
PG-11157 5μM3 . 7 + −2.3 1.1+ −0.2 1.6+ −0.3 1.6+ −0.8 4.6+ −1.6
PG-111458 5μM2 . 4 + −0.5 0.9+ −0.1 1.4+ −0.3 1.2+ −0.5 2.9+ −0.4
PG-11159 5μM4 . 2 + −1.5 1.5+ −0.1 1.5+ −0.2 0.7+ −0.4 3.4+ −0.4
PG-11179 5μM6 . 5 + −2.1 0.9+ −0.2 3.9+ −1.0 0.9+ −0.1 2.1+ −0.6
Tranylcypromine 5μM9 . 3 + −8.1 0.9+ −0.3 2.0+ −0.3 0.8+ −0.1 3.8+ −1.0
DFMO 5mM + PG-11144 5μM 14.6+ −6.1 2.1+ −0.2 372.2+ −45.2 6.4+ −0.2 5.1+ −0.9
DFMO 5mM + PG-11150 5μM7 . 6 + −1.1 1.3+ −0.1 51.3+ −5.0 1.2+ −0.1 6.8+ −2.0
DFMO 5mM + PG-11157 5μM 38.2+ −5.8 1.9+ −0.6 5.2+ −0.5 2.2+ −0.1 10.9+ −2.9
DFMO 5mM + PG-11158 5μM 11.3+ −1.4 1.3+ −0.1 19.0+ −1.4 0.8+ −0.3 3.6+ −1.8
DFMO 5mM + PG-11159 5μM 15.2+ −4.3 2.1+ −1.0 250.2+ −33.7 3.9+ −0.3 4.3+ −1.2
DFMO 5mM + PG-11179 5μM 43.5+ −5.2 1.6+ −0.2 52.7+ −4.6 0.6+ −0.2 10.5+ −1.8
DFMO 5mM + Tranylcypromine 5μM 14.8+ −4.6 1.2+ −0.2 0.8+ −0.1 0.3+ −0.2 4.9+ −1.0
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